• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Oral water soluble contrast for the management of adhesive small bowel obstruction.口服水溶性造影剂用于粘连性小肠梗阻的治疗
Cochrane Database Syst Rev. 2007 Jul 18;2007(3):CD004651. doi: 10.1002/14651858.CD004651.pub3.
2
Oral water soluble contrast for the management of adhesive small bowel obstruction.口服水溶性造影剂用于粘连性小肠梗阻的治疗
Cochrane Database Syst Rev. 2005 Jan 25(1):CD004651. doi: 10.1002/14651858.CD004651.pub2.
3
Oral water soluble contrast for malignant bowel obstruction.用于恶性肠梗阻的口服水溶性造影剂。
Cochrane Database Syst Rev. 2018 Mar 7;3(3):CD012014. doi: 10.1002/14651858.CD012014.pub2.
4
Home treatment for mental health problems: a systematic review.心理健康问题的居家治疗:一项系统综述
Health Technol Assess. 2001;5(15):1-139. doi: 10.3310/hta5150.
5
Signs and symptoms to determine if a patient presenting in primary care or hospital outpatient settings has COVID-19.在基层医疗机构或医院门诊环境中,如果患者出现以下症状和体征,可判断其是否患有 COVID-19。
Cochrane Database Syst Rev. 2022 May 20;5(5):CD013665. doi: 10.1002/14651858.CD013665.pub3.
6
Meta-analysis of oral water-soluble contrast agent in the management of adhesive small bowel obstruction.口服水溶性造影剂用于粘连性小肠梗阻治疗的Meta分析。
Br J Surg. 2007 Apr;94(4):404-11. doi: 10.1002/bjs.5775.
7
Mu-opioid antagonists for opioid-induced bowel dysfunction in people with cancer and people receiving palliative care.用于癌症患者和接受姑息治疗患者的阿片类药物引起的肠道功能障碍的μ-阿片受体拮抗剂。
Cochrane Database Syst Rev. 2018 Jun 5;6(6):CD006332. doi: 10.1002/14651858.CD006332.pub3.
8
Diagnostic test accuracy and cost-effectiveness of tests for codeletion of chromosomal arms 1p and 19q in people with glioma.染色体臂 1p 和 19q 缺失的检测在胶质瘤患者中的诊断准确性和成本效益。
Cochrane Database Syst Rev. 2022 Mar 2;3(3):CD013387. doi: 10.1002/14651858.CD013387.pub2.
9
Population-based interventions for reducing sexually transmitted infections, including HIV infection.基于人群的减少性传播感染(包括艾滋病毒感染)的干预措施。
Cochrane Database Syst Rev. 2004(2):CD001220. doi: 10.1002/14651858.CD001220.pub2.
10
Interventions for preventing distal intestinal obstruction syndrome (DIOS) in cystic fibrosis.预防囊性纤维化患者远端肠梗阻综合征(DIOS)的干预措施。
Cochrane Database Syst Rev. 2018 Jun 12;6(6):CD012619. doi: 10.1002/14651858.CD012619.pub2.

引用本文的文献

1
SBO ACTION: conservative Small Bowel Obstruction management in the Absence of standard ConTrast agents ON outcomes.小肠梗阻治疗行动:在缺乏标准造影剂的情况下对小肠梗阻进行保守治疗的效果。
Br J Surg. 2025 May 31;112(6). doi: 10.1093/bjs/znaf104.
2
Management of Complex Small Bowel Obstructions of Various Etiologies: A Case Series and Literature Review.各种病因所致复杂小肠梗阻的管理:病例系列报告及文献综述
Cureus. 2024 Sep 15;16(9):e69487. doi: 10.7759/cureus.69487. eCollection 2024 Sep.
3
Metastatic Urothelial Cancer Presenting as Small Bowel Obstruction: A Case Report.以小肠梗阻为表现的转移性尿路上皮癌:一例报告
Cureus. 2024 May 28;16(5):e61228. doi: 10.7759/cureus.61228. eCollection 2024 May.
4
Use of barium for diagnosis of colonic perforation leads to challenging barium peritonitis.使用钡剂诊断结肠穿孔会导致具有挑战性的钡剂性腹膜炎。
Trauma Surg Acute Care Open. 2024 Apr 11;9(1):e001431. doi: 10.1136/tsaco-2024-001431. eCollection 2024.
5
THE WATER-SOLUBLE CONTRAST FOR ADHESIVE SMALL BOWEL OBSTRUCTION: ARE THERE ADVANTAGES?水溶性对比剂在黏连性小肠梗阻中的应用:是否有优势?
Arq Bras Cir Dig. 2023 Dec 8;36:e1777. doi: 10.1590/0102-672020230059e1777. eCollection 2023.
6
Water-soluble contrast in the management of adhesive small-bowel obstruction: a Canadian centre's experience with guideline development and implementation.水溶性对比剂在黏连性小肠梗阻管理中的应用:加拿大中心在指南制定和实施方面的经验。
Can J Surg. 2022 Sep 14;65(5):E606-E613. doi: 10.1503/cjs.010020. Print 2022 Sep-Oct.
7
Surgical considerations in cystic fibrosis: what every general surgeon needs to know.囊性纤维化的外科考虑因素:普通外科医生需要了解的知识。
ANZ J Surg. 2022 Oct;92(10):2425-2432. doi: 10.1111/ans.17948. Epub 2022 Aug 3.
8
RISK FACTORS FOR REOPERATION, MORBIDITY, AND MORTALITY IN PATIENTS WITH SMALL BOWEL OBSTRUCTION SUBMITTED TO SURGICAL TREATMENT.接受手术治疗的小肠梗阻患者再次手术、发病和死亡的风险因素。
Arq Bras Cir Dig. 2022 Jun 17;35:e1654. doi: 10.1590/0102-672020210002e1654. eCollection 2022.
9
Rare Case of Small Bowel Obstruction Secondary to Cryptosporidium in a Young Patient With Uncontrolled AIDS.一名艾滋病未得到控制的年轻患者继发隐孢子虫感染导致小肠梗阻的罕见病例。
Cureus. 2021 Jun 29;13(6):e16040. doi: 10.7759/cureus.16040. eCollection 2021 Jun.
10
Use of the Water-Soluble Contrast Medium Gastrografin in Treatment of Adhesive Small Bowel Obstruction in Patients with and Without Chronic Radiation Enteropathy: A Single-Center Retrospective Study.水溶性造影剂泛影葡胺在伴有和不伴有慢性放射性肠炎的粘连性小肠梗阻患者中的应用:一项单中心回顾性研究。
Med Sci Monit. 2021 Mar 27;27:e930046. doi: 10.12659/MSM.930046.

本文引用的文献

1
Randomized controlled trial of Gastrografin in adhesive small bowel obstruction.泛影葡胺用于粘连性小肠梗阻的随机对照试验
ANZ J Surg. 2005 Aug;75(8):672-4. doi: 10.1111/j.1445-2197.2005.03491.x.
2
Randomized clinical study of Gastrografin administration in patients with adhesive small bowel obstruction.泛影葡胺用于粘连性小肠梗阻患者的随机临床研究。
Br J Surg. 2003 May;90(5):542-6. doi: 10.1002/bjs.4150.
3
Small bowel obstruction--the water-soluble follow-through revisited.小肠梗阻——水溶性造影复查
Clin Radiol. 2003 May;58(5):393-7. doi: 10.1016/s0009-9260(02)00538-x.
4
The value of contrast radiology for postoperative adhesive small bowel obstruction.对比造影在术后粘连性小肠梗阻中的价值。
Hepatogastroenterology. 2002 Nov-Dec;49(48):1576-8.
5
Therapeutic value of gastrografin in adhesive small bowel obstruction after unsuccessful conservative treatment: a prospective randomized trial.泛影葡胺在保守治疗失败后的粘连性小肠梗阻中的治疗价值:一项前瞻性随机试验
Ann Surg. 2002 Jul;236(1):1-6. doi: 10.1097/00000658-200207000-00002.
6
Contrast radiography in small intestinal obstruction, a valuable diagnostic tool?小肠梗阻的造影检查,是一种有价值的诊断工具吗?
Eur J Surg. 2001 Feb;167(2):120-4. doi: 10.1080/110241501750070574.
7
Small bowel obstruction due to postoperative adhesions: treatment patterns and associated costs in 110 hospital admissions.术后粘连所致小肠梗阻:110例住院病例的治疗模式及相关费用
Ann R Coll Surg Engl. 2001 Jan;83(1):40-6.
8
Etiology of small bowel obstruction.小肠梗阻的病因
Am J Surg. 2000 Jul;180(1):33-6. doi: 10.1016/s0002-9610(00)00407-4.
9
The use of water-soluble contrast in evaluating clinically equivocal small bowel obstruction.水溶性造影剂在评估临床诊断不明确的小肠梗阻中的应用。
Am Surg. 2000 Mar;66(3):238-42; discussion 242-4.
10
Upper gastrointestinal contrast study in the management of small bowel obstruction--a prospective randomised study.上消化道造影在小肠梗阻管理中的应用——一项前瞻性随机研究。
Eur J Surg. 2000 Jan;166(1):39-43. doi: 10.1080/110241500750009681.

口服水溶性造影剂用于粘连性小肠梗阻的治疗

Oral water soluble contrast for the management of adhesive small bowel obstruction.

作者信息

Abbas S, Bissett I P, Parry B R

机构信息

University of Auckland, Surgery, Parks Road, Auckland, New Zealand.

出版信息

Cochrane Database Syst Rev. 2007 Jul 18;2007(3):CD004651. doi: 10.1002/14651858.CD004651.pub3.

DOI:10.1002/14651858.CD004651.pub3
PMID:17636770
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6465054/
Abstract

BACKGROUND

Adhesions are the leading cause of small bowel obstruction. Gastrografin transit time may allow for the selection of appropriate patients for non-operative management. Some studies have shown when the contrast does not reach the colon after a designated time it indicates complete intestinal obstruction that is unlikely to resolve with conservative treatment. When the contrast does reach the large bowel, it indicates partial obstruction and patients are likely to respond to conservative treatment. Other studies have suggested that the administration of water-soluble contrast is therapeutic in resolving the obstruction.

OBJECTIVES

To determine the reliability of water-soluble contrast media and serial abdominal radiographs in predicting the success of conservative treatment in patients admitted with adhesive small bowel obstruction.Furthermore, to determine the efficacy and safety of water-soluble contrast media in reducing the need for surgical intervention and reducing hospital stay in adhesive small bowel obstruction.

SEARCH STRATEGY

The search was conducted using MESH terms: ''Intestinal obstruction'', ''water-soluble contrast'', "Adhesions" and "Gastrografin". The later combined with the Cochrane Collaboration highly sensitive search strategy for identifying randomised controlled trials and controlled clinical trials.

SELECTION CRITERIA

  1. Prospective studies were included to evaluate the diagnostic potential of water-soluble contrast in adhesive small bowel obstruction.2. Randomised clinical trials were selected to evaluate the therapeutic role.

DATA COLLECTION AND ANALYSIS

  1. Studies that addressed the diagnostic role of water-soluble contrast were critically appraised and data presented as sensitivities, specificities and positive and negative likelihood ratios. Results were pooled and summary ROC curve was constructed.2. A meta-analysis of the data from therapeutic studies was performed using the Mantel -Henszel test using both the fixed effect and random effect models.

MAIN RESULTS

The appearance of water-soluble contrast in the colon on an abdominal X ray within 24 hours of its administration predicts resolution of an adhesive small bowel obstruction with a pooled sensitivity of 0.97, specificity of 0.96. The area under the curve of the summary ROC curve is 0.98. Six randomised studies dealing with the therapeutic role of gastrografin were included in the review, water-soluble contrast did not reduce the need for surgical intervention (OR 0.81, p = 0.3). Meta-analysis of four of the included studies showed that water-soluble contrast did reduce hospital stay compared with placebo (WMD= - 1.83) P<0.001.

AUTHORS' CONCLUSIONS: Published literature strongly supports the use of water-soluble contrast as a predictive test for non-operative resolution of adhesive small bowel obstruction. Although Gastrografin does not cause resolution of small bowel obstruction there is strong evidence that it reduces hospital stay in those not requiring surgery.

摘要

背景

粘连是小肠梗阻的主要原因。泛影葡胺通过时间可用于选择适合非手术治疗的患者。一些研究表明,在规定时间后造影剂未到达结肠表明存在完全性肠梗阻,保守治疗不太可能使其缓解。当造影剂到达大肠时,则表明存在部分梗阻,患者可能对保守治疗有反应。其他研究表明,给予水溶性造影剂对解除梗阻具有治疗作用。

目的

确定水溶性造影剂和系列腹部X线片在预测粘连性小肠梗阻患者保守治疗成功方面的可靠性。此外,确定水溶性造影剂在减少粘连性小肠梗阻手术干预需求和缩短住院时间方面的有效性和安全性。

检索策略

检索使用了医学主题词:“肠梗阻”、“水溶性造影剂”、“粘连”和“泛影葡胺”。后者与Cochrane协作网用于识别随机对照试验和对照临床试验的高敏感性检索策略相结合。

选择标准

1.纳入前瞻性研究以评估水溶性造影剂在粘连性小肠梗阻中的诊断潜力。2.选择随机临床试验以评估其治疗作用。

数据收集与分析

1.对涉及水溶性造影剂诊断作用的研究进行严格评价,并将数据表示为敏感性、特异性、阳性和阴性似然比。汇总结果并构建总结性ROC曲线。2.使用Mantel-Henszel检验,采用固定效应模型和随机效应模型对治疗性研究的数据进行荟萃分析。

主要结果

在给予水溶性造影剂后24小时内,腹部X线片上结肠内出现水溶性造影剂预示粘连性小肠梗阻可缓解,汇总敏感性为0.97,特异性为0.96。总结性ROC曲线下面积为0.98。该综述纳入了6项关于泛影葡胺治疗作用的随机研究,水溶性造影剂并未减少手术干预需求(OR=0.81,p=0.3)。对其中4项纳入研究的荟萃分析表明,与安慰剂相比,水溶性造影剂确实缩短了住院时间(WMD=-1.83),P<0.001。

作者结论

已发表的文献有力支持使用水溶性造影剂作为粘连性小肠梗阻非手术缓解的预测性检查。虽然泛影葡胺不能解除小肠梗阻,但有强有力的证据表明它可缩短不需要手术患者的住院时间。